The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
Open Access
- 17 July 2013
- journal article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 28 (1), 210-212
- https://doi.org/10.1038/leu.2013.216
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- ABT-199, a new Bcl-2–specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopeniaBlood, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working GroupLeukemia, 2012
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory DiseaseJournal of Clinical Oncology, 2012
- ABT-737 is highly effective against molecular subgroups of multiple myelomaBlood, 2011
- Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experienceLeukemia, 2011
- A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell linesHaematologica, 2010
- Mutations in TP53 are exclusively associated with del(17p) in multiple myelomaHaematologica, 2010
- Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?Cell Death & Differentiation, 2008
- Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaCancer Cell, 2006